Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the mechanism(s) of resistance to the anti-epidermal
growth factor receptor (EGFR) antibody panitumumab given in combination with irinotecan in
metastatic colorectal carcinoma (mCRC) patients with wild-type Kirsten rat sarcoma-2 virus
oncogene (KRAS) tumor status at the time of initial diagnosis.